Samsung Bioepis has secured the right to sell “Opuviz,” a biosimilar (biopharmaceutical copy drug) of the blockbuster drug “Eylea,” which generates annual sales of KRW 14 trillion, in the United States starting in 2027.

Samsung Bioepis announced on the 12th that it has signed a U.S. sales license agreement for the 2mg formulation of Eylea with its developers Regeneron and Bayer. Under this agreement, Samsung Bioepis will be able to launch Opuviz in the U.S. in January 2027. Following the patent settlement in Europe in January this year, the company has now completed a patent agreement in the U.S. as well, opening the way for overseas sales of Opuviz.

Eylea is an ophthalmic treatment for diseases such as neovascular age-related macular degeneration, with global sales in 2024 reaching around KRW 14 trillion, of which KRW 9 trillion comes from the U.S. market. Based on this agreement, Samsung Bioepis plans to launch Opuviz in the U.K. from January this year, in European countries from April, and in the U.S. market in 2027.

Popular News